Triggerable Oxygen Nanobubbles for Drug Delivery, Diagnosis, and Enhanced Survival

Back to all technologies
Download as PDF
2015-IRUD-66920
Ultrasound has a broad clinical utility in prostate cancer diagnosis because of its diagnostic capabilities, ease of use, portability, and ability to reveal fluid flow and structure of anatomy in vivo. Several commercial ultrasound contrast agents exist, but are synthesized using fluorinated gases or air and have sizes in the micron range. Past efforts have at most synthesized ~500 nm-sized particles and primarily functioned as a contrast agent. These large particles fail to take advantage of the enhanced permeability and retention (EPR) effect.

Researchers at Purdue University have capitalized on the broad clinical utility of ultrasound. This technology is the first nanosized oxygen- and cargo-bearing bubbles that can be tuned to first image at a low intensity and selectively release cargo upon an ultrasound trigger at a higher intensity.

Advantages:
-Enhanced permeability and retention inside tumor vasculature.
-Controlled drug release
-Avoids immune system response.
-Transport of material through the encapsulating layer.

Potential Applications:
-Pharmaceutical industry
-Medical/Healthcare
-Cancer drug delivery and diagnosis
-Therapy for cancerous tumors
Oct 2, 2015
Utility Patent
United States
9,968,692
May 15, 2018

Mar 7, 2018
CIP-Patent
United States
(None)
(None)

Apr 14, 2015
Provisional-Patent
United States
(None)
(None)

Nov 5, 2014
Provisional-Patent
United States
(None)
(None)

Oct 2, 2014
Provisional-Patent
United States
(None)
(None)
Purdue Office of Technology Commercialization
1801 Newman Road
West Lafayette, IN 47906

Phone: (765) 588-3475
Fax: (765) 463-3486
Email: otcip@prf.org